<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665323</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-60120-450</org_study_id>
    <nct_id>NCT04665323</nct_id>
  </id_info>
  <brief_title>An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.</brief_title>
  <official_title>An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FOP burden of illness (BoI) survey aims to assess the impact of the burden of FOP on&#xD;
      patients and their families. The study is being conducted online and available for residents&#xD;
      in Argentina, Brazil, Canada, France, Germany, Italy, Japan, Mexico, Poland, Russia, South&#xD;
      Korea, Spain, Sweden, the US, and the UK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life of people living with FOP and their family members, measured using the EuroQol health-related quality of life (QoL) questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life of people living with FOP and their family members, measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caregiver burden for the parent primary caregiver, measured using the Zarit Burden Interview (ZBI)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the emotional burden on family members</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function of the person living with FOP, measured using the FOP Physical Function Questionnaire (FOP-PFQ).</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint function of the person living with FOP, measured using Patient-Reported Mobility Assessment (PRMA).</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the types of healthcare services utilized by the person living with FOP over the last two years</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the frequency of utilization of healthcare services by the person living with FOP over the last two years.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the impact of FOP on modifications to the living environment (e.g. home modifications) and travels.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the expenses paid by the family for the care of the person living with FOP</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to bespoke questionnaire describing the Impact of FOP on education, employment, and career choices for people living with FOP and their family members</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">411</enrollment>
  <condition>Fibrodysplasia Ossificans Progressiva</condition>
  <arm_group>
    <arm_group_label>People living with FOP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Parent or legal guardian primary caregivers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Parent or legal guardian</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Siblings</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Convenience Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals meeting one of the two categories below (A or B) are eligible to&#xD;
             participate: A. Any individual with FOP, of any age; B. Any individual who is a family&#xD;
             member of a person with FOP (i.e. either a parent / legal guardian or a sibling) and&#xD;
             who is aged 18 years and older&#xD;
&#xD;
          2. All adult participants and parents / legal guardians of minors should provide informed&#xD;
             consent before starting filling out the survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Any individuals who are unable to complete the online survey independently or to get&#xD;
        assistance to physically enter the answers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis Ossificans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

